All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-06-29T13:32:41.000Z

Initial results of cilta-cel, a CAR T-cell therapy, in earlier lines of treatment

Bookmark this article

During the 2021 ASCO Annual Meeting and the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Mounzer Agha, UPMC Hillman Cancer Center, Pittsburgh, US. We asked, What are the initial results of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, in earlier lines of treatment?

In this video, Agha presents data from the CARTITUDE-2 trial (NCT04133636) on cilta-cel, a BCMA-directed CAR T-cell therapy, for patients with relapsed/refractory multiple myeloma (RRMM), following 1–3 prior lines of therapy. The primary objective of the study was measurable residual disease (MRD) negativity, while secondary objectives included the overall response rate and duration of response. Agha highlights a manageable safety profile, with the majority of side effects that weren't hematologic being mild, and Grade 3/4 toxicity was uncommon.

 

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox